Pfizer (Sweden)

Assessing the consistency of overall survival extrapolations in Swedish health technology assessment reports of oncology treatments using extended follow-up data

BACKGROUND: Long-term overall survival (OS) extrapolations underpin cost-effectiveness appraisals, projecting survival beyond trial follow-up. We aimed to compare extrapolations presented in manufacturer submissions and appraisals published by the Swedish Dental and Pharmaceutica...